Using thrombocytopenia modeling to investigate the mechanisms underlying platelet depletion induced by pan‐proteasome inhibitors

por Lignet, Floriane, Becker, Andreas D., Gimmi, Claude, Rohdich, Felix, El Bawab, Samer
Publicado 2021

Model‐Based Evaluation of Radiation and Radiosensitizing Agents in Oncology

por Cardilin, Tim, Almquist, Joachim, Jirstrand, Mats, Zimmermann, Astrid, El Bawab, Samer, Gabrielsson, Johan
Publicado 2017

Model-based assessment of combination therapies – ranking of radiosensitizing agents in oncology

por Baaz, Marcus, Cardilin, Tim, Lignet, Floriane, Zimmermann, Astrid, El Bawab, Samer, Gabrielsson, Johan, Jirstrand, Mats
Publicado 2023

Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agents

por Cardilin, Tim, Almquist, Joachim, Jirstrand, Mats, Zimmermann, Astrid, Lignet, Floriane, El Bawab, Samer, Gabrielsson, Johan
Publicado 2019

Exposure-response modeling improves selection of radiation and radiosensitizer combinations

por Cardilin, Tim, Almquist, Joachim, Jirstrand, Mats, Zimmermann, Astrid, Lignet, Floriane, El Bawab, Samer, Gabrielsson, Johan
Publicado 2021

A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug‐Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide

por Lüpfert, Christian, Dyroff, Martin, von Richter, Oliver, Gallemann, Dieter, El Bawab, Samer, Dolgos, Hugues, Jung, Don, Hecht, Stefan, Johne, Andreas
Publicado 2018

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

por Xiong, Wenyuan, Friese‐Hamim, Manja, Johne, Andreas, Stroh, Christopher, Klevesath, Manfred, Falchook, Gerald S., Hong, David S., Girard, Pascal, El Bawab, Samer
Publicado 2021

Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1

por Vugmeyster, Yulia, Wilkins, Justin, Koenig, Andre, El Bawab, Samer, Dussault, Isabelle, Ojalvo, Laureen S., De Banerjee, Samrita, Klopp‐Schulze, Lena, Khandelwal, Akash
Publicado 2020

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

por van Bussel, Mark T. J., Awada, Ahmad, de Jonge, Maja J. A., Mau-Sørensen, Morten, Nielsen, Dorte, Schöffski, Patrick, Verheul, Henk M. W., Sarholz, Barbara, Berghoff, Karin, El Bawab, Samer, Kuipers, Mirjam, Damstrup, Lars, Diaz-Padilla, Ivan, Schellens, Jan H. M.
Publicado 2020

Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies

por Haselmayer, Philipp, Camps, Montserrat, Muzerelle, Mathilde, El Bawab, Samer, Waltzinger, Caroline, Bruns, Lisa, Abla, Nada, Polokoff, Mark A., Jond-Necand, Carole, Gaudet, Marilène, Benoit, Audrey, Bertschy Meier, Dominique, Martin, Catherine, Gretener, Denise, Lombardi, Maria Stella, Grenningloh, Roland, Ladel, Christoph, Petersen, Jørgen Søberg, Gaillard, Pascale, Ji, Hong
Publicado 2014

Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases

por Clarke, Paul A, Ortiz-Ruiz, Maria-Jesus, TePoele, Robert, Adeniji-Popoola, Olajumoke, Box, Gary, Court, Will, Czasch, Stephanie, El Bawab, Samer, Esdar, Christina, Ewan, Ken, Gowan, Sharon, De Haven Brandon, Alexis, Hewitt, Phillip, Hobbs, Stephen M, Kaufmann, Wolfgang, Mallinger, Aurélie, Raynaud, Florence, Roe, Toby, Rohdich, Felix, Schiemann, Kai, Simon, Stephanie, Schneider, Richard, Valenti, Melanie, Weigt, Stefan, Blagg, Julian, Blaukat, Andree, Dale, Trevor C, Eccles, Suzanne A, Hecht, Stefan, Urbahns, Klaus, Workman, Paul, Wienke, Dirk
Publicado 2016